Actinium Pharmaceuticals, Inc. (ATNM)
After hours:
| Previous close | 9.85 |
| Open | 9.84 |
| Bid | 9.33 x 800 |
| Ask | 9.73 x 800 |
| Day's range | 9.46 - 9.95 |
| 52-week range | 4.00 - 10.24 |
| Volume | |
| Avg. volume | 407,380 |
| Market cap | 291.878M |
| Beta (5Y monthly) | 0.09 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Actinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced it will host a KOL webinar on Monday, May 20, 2024, at 8:00 AM ET. The call will highlight and discuss Actinium's recently announced Iomab-ACT commercial CAR T-cell trial being conducted at the University of Texas Southwestern (UTSW) including the study design, objectives and potential commercial opp
- PR Newswire
Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 SIERRA Trial
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced that results from the Phase 3 SIERRA trial of Iomab-B have been accepted for an oral presentation and poster presentation at the 2024 European Hematology Association (EHA) Hybrid Congress being held June 13 – 16, 2024, in Madrid, Spain. The Phase 3 SIERRA trial enrolled 153 patients ages 55 and above
- PR Newswire
Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced that five abstracts have been accepted for presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting being held June 8 – 11, 2024, in Toronto, Canada. The abstracts will feature results from the Phase 3 SIERRA trial of Iomab-B, a CD45 targeting ARC with the Iodin
